The Company has more than 45 proprietary and partnered product candidates in development
Ablynx participates and presents at IR and scientific conferences
Ablynx is listed on Euronext Brussels under the ticker symbol ABLX.
ABLYNX'S PARTNER, MERCK KGaA, HAS PRESENTED NEW DATA FROM A PHASE Ib PSORIASIS STUDY OF THE BI-SPECIFIC ANTI-IL-17A/F NANOBODY AT THE ANNUAL AAD CONFERENCE06 March 2017
ABLYNX ANNOUNCES 2016 FULL YEAR RESULTS23 February 2017
ABLYNX WILL ANNOUNCE ITS 2016 FULL YEAR RESULTS WITH WEBCAST ON 23 FEBRUARY 201716 February 2017
TITAN study - Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura